CRP and neoplasm: The association between baseline CRP elevation and inferior OS (HR = 3.337; p=0.044) underscores systemic inflammation’s role in ES-SCLC progression-a finding consistent with mechanisms linking interleukin-6-driven inflammation to immunosuppression and tumor aggressiveness (8–11).